A critical review of methotrexate clinical interactions: role of transporters

References

• Kawase A, Yamamoto T, Egashira S, et al. Stereoselective inhibition of methotrexate excretion by glucuronides of nonsteroidal anti-inflammatory drugs via multidrug resistance proteins 2 and 4. J Pharmacol Exp Ther. 2016;356(2):366–374.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004;64(16):5804–5811.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui C-H, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471.
   PubMed Web of Science ®Google Scholar
• Chan AJ, Rajakumar I. High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract. 2014;20(2):93–99.
   PubMed Web of Science ®Google Scholar
• Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report–should the practice be changed? Chemotherapy. 2011;57(3):225–229.
   PubMed Web of Science ®Google Scholar
• Ranchon F, Vantard N, Henin E, et al. Delayed methotrexate elimination: incidence, interaction with antacid drugs, and clinical consequences? Hematol Oncol. 2018;36(2):399–406.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui C-H, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30(3):963–965.
   PubMed Web of Science ®Google Scholar
• Gaies E, Jebabli N, Trabelsi S, et al. Methotrexate side effects: review article. J Drug Metab Toxicol. 2012;3(4):1–5.
   Google Scholar
• Hall JJ, Bolina M, Chatterley T, et al. Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors: a narrative review of the literature. Ann Pharmacother. 2017;51(2):163–178.
   PubMed Web of Science ®Google Scholar
• Wang X, Song Y, Wang J, et al. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis. Int J Clin Pharm. 2020;42(1):23–30.
   PubMed Web of Science ®Google Scholar
• Ikemura K, Hiramatsu S-I, Shinogi Y, et al. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Sci Rep. 2019;9(1):1–10.
   PubMedGoogle Scholar
• Steele WH, Lawrence JR, Stuart JF, et al. The protein binding of methotrexate in the serum of patients with neoplastic disease. Cancer Chemother Pharmacol. 1981;7(1):61–64.
   PubMed Web of Science ®Google Scholar
• Steinberg SE, Campbell CL, Bleyer WA, et al. Enterohepatic circulation of methotrexate in rats in vivo. Cancer Res. 1982 Apr;42(4):1279–1282.
   PubMed Web of Science ®Google Scholar
• Valerino DM, Johns DG, Zaharko DS, et al. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid. Biochem Pharmacol. 1972 Mar 15;21(6):821–831.
   PubMed Web of Science ®Google Scholar
• Redetzki HM, Redetzki JE, Elias AL. Resistance of the rabbit tomethotrexate: isolation of a drug metabolite with decreased cytotoxicity. Biochem Pharmacol. 1966 Apr;15(4):425–433.
   PubMed Web of Science ®Google Scholar
• Steele WH, Lawrence JR, Stuart JF, et al. The protein binding of methotrexate by the serum of normal subjects. Eur J Clin Pharmacol. 1979 Jun 12;15(5):363–366.
   PubMed Web of Science ®Google Scholar
• Beorlegui B, Aldaz A, Ortega A, et al. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024–1027.
   PubMed Web of Science ®Google Scholar
• Holmboe L, Andersen AM, Mørkrid L, et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106–114.
   PubMed Web of Science ®Google Scholar
• McGuire JJ, Hsieh P, Bertino JR. Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate. Biochem Pharmacol. 1984 Apr 15;33(8):1355–1361.
   PubMed Web of Science ®Google Scholar
• Rhee MS, Galivan J. Conversion of methotrexate to 7-hydroxymethotrexate and 7-hydroxymethotrexate polyglutamates in cultured rat hepatic cells. Cancer Res. 1986 Aug;46(8):3793–3797.
   PubMed Web of Science ®Google Scholar
• McBride A, Antonia SJ, Haura EB, et al. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012;25(4):477–485.
   PubMedGoogle Scholar
• Hannoodee M, Mittal M. Methotrexate. StatPearls [Internet]: StatPearls Publishing; 2021.
   Google Scholar
• Okada M, Fujii H, Suga Y, et al. Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. J Pharm Health Care Sci. 2017;3(1):7.
   PubMedGoogle Scholar
• Patanè M, Ciriaco M, Chimirri S, et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. Adv Pharmacol Sci. 2013;2013:313858.
   PubMedGoogle Scholar
• Tao D, Wang H, Xia F, et al. Pancytopenia due to possible drug–drug interactions between low-dose methotrexate and proton pump inhibitors. Drug Healthc Patient Saf. 2022 Dec 31;14:75–78.
   PubMed Web of Science ®Google Scholar
• Pivovarov K, Zipursky JS. Low-dose methotrexate toxicity. Cmaj. 2019 Apr 15;191(15):E423.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016 Dec;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Ranchon F. Methotrexate/pantoprazole interaction. Reactions. 2011;1364:13.
   Google Scholar
• Hsu M. Methotrexate/celecoxib interaction. Reactions. 2016;1583:735–739.
   Google Scholar
• Rachana P, Anuradha H, Mounika R. Stevens Johnson syndrome-toxic epidermal necrolysis overlap secondary to interaction between methotrexate and etoricoxib: a case report. J clin diagn res. 2015;9(7):FD01.
   PubMedGoogle Scholar
• Iwaki M, Shimada H, Irino Y, et al. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull. 2017;40(6):926–931.
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Kusuhara H, Kondo T, et al. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther. 2007;322(3):1162–1170.
   PubMed Web of Science ®Google Scholar
• Nanke Y, Kotake S, Akama H, et al. Pancytopenia and colitis with Clostridium difficile in a rheumatoid arthritis patient taking methotrexate, antibiotics and non-steroidal anti-inflammatory drugs. Clin Rheumatol. 2001;20(1):73–75.
   PubMed Web of Science ®Google Scholar
• Maiche A. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet. 1986;327(8494):1390.
   Google Scholar
• Furst DE, Herman RA, Koehnke R, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci. 1990;79(9):782–786.
   PubMed Web of Science ®Google Scholar
• Dereksson K. Methotrexate interaction. Reactions. 2007;1178:17.
   Google Scholar
• Thyss A, Kubar J, Milano G, et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet. 1986;327(8475):256–258.
   Google Scholar
• Daly H, Boyle J, Roberts C, et al. Interaction between methotrexate and non-steroidal anti-inflammatory drugs. Lancet. 1986;327(8480):557.
   Google Scholar
• Maronas-Jimenez L. Cotrimoxazole/ibuprofen/methotrexate. Reactions. 2014;1501:16–17.
   Google Scholar
• Preet Singh Y, Aggarwal A, Misra R, et al. Low-dose methotrexate-induced pancytopenia. Clin Rheumatol. 2007;26(1):84–87.
   PubMed Web of Science ®Google Scholar
• Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061.
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Agrawal NG, Wong PH, et al. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol. 2001;41(10):1120–1130.
   PubMed Web of Science ®Google Scholar
• Skeith K, Russell A, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol. 1990;17(8):1008–1010.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Koren G, Shore A, et al. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol. 1990;17(11):1469–1473.
   PubMed Web of Science ®Google Scholar
• Hübner G, Sander O, Degner F, et al. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1997;24(5):845–851.
   PubMed Web of Science ®Google Scholar
• Colebatch AN, Marks JL, Edwards CJ. Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (Acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011;11:CD008872. DOI:10.1002/14651858.CD008872.pub2. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008872.pub2/full
   PubMed Web of Science ®Google Scholar
• Iqbal MP, Baig JA, Ali AA, et al. The effects of non‐steroidal anti‐inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos. 1998;19(3):163–167.
   PubMed Web of Science ®Google Scholar
• Tracy T, Worster T, Bradley J, et al. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1994;37(5):453–456.
   PubMed Web of Science ®Google Scholar
• Stewart CF, Fleming RA, Arkin CR, et al. Coadministration of naproxen and low‐dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther. 1990;47(4):540–546.
   PubMed Web of Science ®Google Scholar
• Sathi N, Dawson J. Methotrexate-induced pancytopenia associated with co-prescription of penicillin and trimethoprim. Clin Rheumatol. 2007;26(1):134–135.
   PubMed Web of Science ®Google Scholar
• Kramer I. Methotrexate/piperacillin/tazobactam interaction. Reactions. 1823;235(26):2020.
   Google Scholar
• de Miguel D. Gemfibrozil/methotrexate/piperacillin/tazobactam interaction. Reactions. 2008;1231:6.
   Google Scholar
• Krämer I, Rosentreter J, Fried M, et al. Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient. J Oncol Pharm Pract. 2021;27(4):1000–1004.
   PubMed Web of Science ®Google Scholar
• Zarychanski R, Wlodarczyk K, Ariano R, et al. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J Antimicrob Chemother. 2006;58(1):228–230.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Sawada Y, Matsushita Y, et al. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother. 1997;31(10):1261–1262.
   PubMed Web of Science ®Google Scholar
• Herrick A, Grennan D, Aarons L. Lack of interaction between methotrexate and penicillins. Rheumatology (Oxford). 1999;38(3):284–285.
   PubMed Web of Science ®Google Scholar
• Titier K, Lagrange F, Péhourcq F, et al. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit. 2002;24(4):570–572.
   PubMed Web of Science ®Google Scholar
• Ronchera C, Hernandez T, Peris J, et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit. 1993;15(5):375–379.
   PubMed Web of Science ®Google Scholar
• Aikoye A. Amoxicillin/ciprofloxacin/methotrexate interaction. Reactions. 2015;1542: 27–14.
   Google Scholar
• Arslan A, Zain MA, Mukhtar M, et al. Methotrexate and doxycycline interaction: a rare cause of pancytopenia. BMJ Case Reports CP. 2019;12(5):e229296.
   PubMedGoogle Scholar
• Dalle J-H, Auvrignon A, Vassal G, et al. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol. 2002;24(4):321–322.
   PubMed Web of Science ®Google Scholar
• Spoldi L. Ciprofloxacin/methotrexate interaction. Reactions. 2014;1483: 33–11.
   Google Scholar
• Aouinti I. Ciprofloxacin/methotrexate interaction. Reactions. 2013;1467:11–31.
   Google Scholar
• Bartha P, Bron R, Levy Y. Fatal pancytopenia and methotrexate-trimethoprim-sulfamethoxazole interaction. Harefuah. 2004;143(6):398–400. 464.
   PubMedGoogle Scholar
• Beach BJ, Woods WG, Howell SB. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia. Am J Pediatric Hematol Oncol. 1981;3(2):115–119.
   PubMedGoogle Scholar
• Cudmore J. Cotrimoxazole/methotrexate interaction. Reactions. 2014;1499:12–13.
   Google Scholar
• Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr. 1990;117(5):823–826.
   PubMed Web of Science ®Google Scholar
• Thomas DR, Dover JS, Camp R. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol. 1987;17(6):1055–1056.
   PubMed Web of Science ®Google Scholar
• Kochhar S, Bommu VJL, Kocur M, et al. A unique interaction of methotrexate and nitrofurantoin resulting in irreversible pulmonary fibrosis. Cureus. 2022;14:1.
   Web of Science ®Google Scholar
• Demir E, Sütcüoğlu O, Demir B, et al. A possible interaction between favipiravir and methotrexate: drug-induced hepatotoxicity in a patient with osteosarcoma. J Oncol Pharm Pract. 2021;28(2):445–448. DOI:10.1177/10781552211031304.
   PubMed Web of Science ®Google Scholar
• Wedemeyer R-S BH. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–211.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Doki K, Homma M, et al. Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44–49.
   PubMed Web of Science ®Google Scholar
• Narumi K, Sato Y, Kobayashi M, et al. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug–drug interactions mediated by organic anion transporter 3. Biopharm Drug Dispos. 2017;38(9):501–508.
   PubMed Web of Science ®Google Scholar
• Boerrigter E, Crul M. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin. Ann Pharm Fr. 2017;75(5):344–348. DOI:10.1016/j.pharma.2017.06.002.
   PubMedGoogle Scholar
• Bauters TG, Verlooy J, Robays H, et al. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316–318.
   PubMedGoogle Scholar
• Tröger U, Stötzel B, Martens-Lobenhoffer J, et al. Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Bmj. 2002;324(7352):1497.
   PubMedGoogle Scholar
• Yuan Z. Methotrexate/omeprazole interaction. Reactions. 2016;1610:101–116.
   Google Scholar
• Reeves DJ, Moore ES, Bascom D, et al. Retrospective evaluation of methotrexate elimination when co‐administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565–571.
   PubMed Web of Science ®Google Scholar
• Bain E, Birhiray RE, Reeves DJ. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination. Ann Pharmacother. 2014;48(2):292–296.
   PubMed Web of Science ®Google Scholar
• Vakily M, Amer F, Kukulka MJ, et al. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol. 2005;45(10):1179–1186.
   PubMed Web of Science ®Google Scholar
• Bezabeh S, Mackey AC, Kluetz P, et al. Accumulating evidence for a drug–drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550–554.
   PubMed Web of Science ®Google Scholar
• Loue C, Garnier N, Bertrand Y, et al. High methotrexate exposure and toxicity in children with t (9; 22) positive acute lymphoblastic leukaemia treated with imatinib. J Clin Pharm Ther. 2015;40(5):599–600.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270.
   PubMed Web of Science ®Google Scholar
• Pommert L, Liberio N, Ng JS, et al. Concurrent imatinib dosing with high-dose methotrexate leads to acute kidney injury and delayed methotrexate clearance in pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2021;43(2):e296–e300.
   PubMedGoogle Scholar
• van Hest R. Imatinib/methotrexate interaction. Reactions. 2008;1228:15.
   Google Scholar
• Ramsey LB, Mizuno T, Vinks AA, et al. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatr Blood Cancer. 2019;66(5):e27618.
   PubMed Web of Science ®Google Scholar
• Inose R, Takahashi K, Nanno S, et al. Calcium channel blockers possibly delay the elimination of plasma methotrexate in patients receiving high-dose methotrexate therapy. J Chemother. 2019;31(1):30–34.
   PubMed Web of Science ®Google Scholar
• Maharaj A. Lithium/methotrexate interaction. Reactions. 2015;1544: 145–28.
   Google Scholar
• Parentelli AS, Phulpin‐Weibel A, Mansuy L, et al. Drug–drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(2):340–341.
   PubMed Web of Science ®Google Scholar
• Lou U, Kwok J, Nguyen TA, et al. Effect of levetiracetam on time to high‐dose methotrexate clearance in patients with hematologic malignancies. J Clin Pharmacol. 2020;60(3):324–330.
   PubMed Web of Science ®Google Scholar
• Reeves D, DiDominick S, Finn S, et al. Methotrexate elimination when coadministered with levetiracetam. Ann Pharmacother. 2016;50(12):1016–1022.
   PubMed Web of Science ®Google Scholar
• DeFino CE, Barreto JN, Pawlenty AG, et al. Lack of drug interaction between levetiracetam and high‐dose methotrexate in patients with lymphoma. Pharmacother J Human Pharmacol Drug Ther. 2021;41(5):430–439.
   Google Scholar
• Huang C, Xia F, Xue L, et al. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer Chemother Pharmacol. 2020;85(2):433–441.
   PubMed Web of Science ®Google Scholar
• Kates RE, Tozer TN, Sorby DL. Increased methotrexate toxicity due to concurrent probenecid administration. Biochem Pharmacol. 1976;25(13):1485–1488.
   PubMed Web of Science ®Google Scholar
• Kates R, Tozer T. Biliary secretion of methotrexate in rats and its inhibition by probenecid. J Pharm Sci. 1976;65(9):1348–1352.
   PubMed Web of Science ®Google Scholar
• Ueda K, Kato Y, Komatsu K, et al. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther. 2001;297(3):1036–1043.
   PubMed Web of Science ®Google Scholar
• Bourke RS, Chheda G, Bremer A, et al. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res. 1975;35(1):110–116.
   PubMed Web of Science ®Google Scholar
• Nierenberg DW. Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1983;226(1):1–6.
   PubMed Web of Science ®Google Scholar
• Aherne GW, Piall E, Marks V, et al. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J. 1978;1(6120):1097–1099.
   PubMedGoogle Scholar
• Basin K, Escalante A, Beardmore T. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol. 1991;18(4):609–610.
   PubMed Web of Science ®Google Scholar
• Levêque D, Santucci R, Gourieux B, et al. Pharmacokinetic drug–drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol. 2011;4(6):743–750.
   PubMedGoogle Scholar
• Tugnet N. Hydroxychloroquine/methotrexate interaction. Reactions. 2012;1405:9.
   Google Scholar
• Johnston D. Clofarabine/methotrexate interaction. Reactions. 2008;1201:10.
   Google Scholar
• Dao K. Chloral hydrate/methotrexate interaction. Reactions. 2013;1452:18.
   Google Scholar
• Kivity S, Zafrir Y, Loebstein R, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014;13(11):1109–1113.
   PubMed Web of Science ®Google Scholar
• Al-Khalili O, Mikuls TR, O’Dell JR, et al. Methotrexate and NSAIDs in rheumatoid arthritis—Confirmation of a known NSAIDs adverse effect rather than a dangerous combination. Pharmacoepidemiol Drug Saf. 2018;27(12):1429.
   PubMed Web of Science ®Google Scholar
• Kreft B, Wohlrab J, Bramsiepe I, et al. Etoricoxib‐induced toxic epidermal necrolysis: successful treatment with infliximab. J Dermatol. 2010;37(10):904–906.
   PubMed Web of Science ®Google Scholar
• Svanström H, Lund M, Melbye M, et al. Concomitant use of low‐dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2018;27(8):885–893.
   PubMed Web of Science ®Google Scholar
• Furst D. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Rheumatology. 1995;34(suppl_4):20–25.
   Google Scholar
• Cheng Y, Chen M, Zhuang Q, et al. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(5):e28858.
   PubMed Web of Science ®Google Scholar
• Uwai Y, Saito H, K-I I. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000;409(1):31–36.
   PubMed Web of Science ®Google Scholar
• Danziger LH, Horn KS. Beta-lactam antibiotics. Manjunath P. Pai, Jennifer J. Kiser, Paul O. Gubbins, Keith A. Rodvold. In: Drug interactions in infectious diseases: antimicrobial drug interactions. Switzerland: Humana Press, Cham; 2018. p. 1–56. DOI:10.1007/978-3-319-72416-4_1.
   Google Scholar
• Chioukh R, Noel-Hudson M-S, Ribes S, et al. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3. Drug Metab Dispos. 2014;42(12):2041–2048.
   PubMed Web of Science ®Google Scholar